Ioglicinate, contrast agent, is used in computed tomography.

Bumadizone is a non-steroidal anti-inflammatory drug exerting analgesic, antipyretic and anti-inflammatory properties. It has been studied in the treatment of rheumatoid diseases.

Fosfonet sodium (or phosphonoacetate sodium), an organophosphorus compound, was found to be a specific inhibitor of the virus-induced DNA polymerases and thus could inhibit specifically the replication of herpes-viruses.

Niperotidine is an H2 antagonist structurally related to ranitidine. H2 antagonists inhibit gastric acid secretion by selectively blocking histamine receptor type 2. Niperotidine was proposed for the treatment of peptic ulcer. Bedtime dose of niperotidine inhibits nocturnal gastric acid secretion in healthy subjects. The duration of niperotidine action was 5 to 7 hours. Twenty-five cases of acute hepatitis (including one death from fulminant hepatitis) associated with niperotidine use were reported in Italy between March and August 1995 and drug was withdrawn from the market. The methylenedioxy group of niperotidine is known to undergo metabolism to catechol and quinone metabolites.

Tisopurine (or Thiopurinol) was used in the treatment of gout. This drug reduces uric acid concentrations by interfering with the early stages of its synthesis, thus avoiding increased blood concentrations of hypoxanthine and xanthine. In addition, it was discovered, that tisopurine caused acute hepatitis.

Isobromidione is an indanedione. It was used as a uricosuric agent.

Piromidic acid, a quinolone antibiotic has an inhibitory effect against hepatic stages of P. falciparum and P. yoelii yoelii, and has a potential for treatment or prevention of malaria through their unique antiparasitic effect against erythrocytic and hepatic stages of Plasmodium.

AFALANINE was developed by Medea Research in Italy and licensed to Pulitzer. Phase III clinical trials of MR 708 were completed by Pulitzer. Antidepressant; Antiparkinsonian; Neuroprotectant; Nootropic, Dopamine receptor agonist, was used to treat Major depressive disorder.

Lafutidine is a novel histamine H2 antagonist with gastroprotective activity. Lafutidine exhibited potent and long-lasting H2 antagonism and prolonged antisecretion. In addition, lafutidine showed a gastroprotective effect against noxious agents-induced gastric mucosal damage through capsaicin-sensitive afferent nerves. Lafutidine showed antiulcer activities against acute ulcer models, prevented gastric ulcer relapse of acetic ulcer. Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea, vomiting and dizziness.It also activates calcitonin gene-related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of Helicobacter pylori to gastric cells

Spaglumic acid (NAAG) is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate. Spaglumic acid is a mast cell stabilizer. Thus it is used in allergic conditions such as allergic conjunctivitis. Specifically spaglumic acid is approved in Portugal under the brand name Naabak and in Greece under the brand name Naaxia for use in patients with allergic conjunctivitis. Spaglumic Acid is a peptide neurotransmitter and the third-most-prevalent neurotransmitter in the mammalian nervous system. It is a weak activator of NMDA receptors and a highly selective agonist for mGlu3 receptors. Spaglumic Acid is neuroprotective under non-hydrolysing conditions in vivo.